Concepedia

Publication | Closed Access

Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial

DOI

22

Citations

28

References

2018

Year

Arzu Yorgancıoğlu, Ferda Öner Erkekol, Dilşad Mungan, Münevver Erdinç, Bilun Gemicioğlu, Ferhan Özşeker, Papatya Bayrak Değirmenci, Sibel Naycı, Aykut Çilli, Füsun Erdenen,
International Archives of Allergy and Immunology

Abstract

Omalizumab had a significant effect on asthma outcomes and this effect was maintained over 5 years. The drug was found to be generally safe and treatment compliance was good.

References

YearCitations

Page 1